|
|
Post by awesomo on Aug 11, 2021 15:37:53 GMT -5
The jump in collaboration revenue is encouraging.
|
|
|
|
Post by peppy on Aug 11, 2021 15:38:59 GMT -5
|
|
|
|
Post by dh4mizzou on Aug 11, 2021 15:40:35 GMT -5
Did I see EPS was (0.11) for the QTR?
How did that compare to the consensus?
|
|
|
|
Post by alethea on Aug 11, 2021 15:41:09 GMT -5
Thank you Peppy for the LINK to the Conference Call a 5pm EDT.
|
|
|
|
Post by lookforgrowth on Aug 11, 2021 15:51:05 GMT -5
Will there a be a Shoutbox provided for the call?
|
|
|
|
Post by alethea on Aug 11, 2021 16:06:07 GMT -5
Is the Shout Box turned on?
|
|
|
|
Post by peppy on Aug 11, 2021 16:07:51 GMT -5
BINGO. Working on several Formulations for new collaborators, (Including NRx Zyesami announced last week.)  |
|
|
|
Post by peppy on Aug 11, 2021 16:09:59 GMT -5
|
|
|
|
Post by mango on Aug 11, 2021 16:20:01 GMT -5
BINGO. Working on several Formulations for new collaborators, (Including NRx Zyesami announced last week.) Oh wow a NEW CHEMICAL ENTITY for the Thirona partnership. I like it! ALK-5 aka Transforming growth factor beta receptor I. Involved in a ton of biological processes. This will be exciting to see the development of this NCE unfold. |
|
|
|
Post by mango on Aug 11, 2021 16:22:37 GMT -5
FBM5712 is a novel small molecule inhibitor of the ALK-5 kinase (the transforming growth factor-β (TGF-β) receptor kinase)
|
|
|
|
Post by peppy on Aug 11, 2021 16:23:40 GMT -5
|
|
|
|
Post by mango on Aug 11, 2021 16:24:13 GMT -5
Was anything mentioned about the new partnership with NRx?
|
|
|
|
Post by peppy on Aug 11, 2021 16:26:31 GMT -5
|
|
|
|
Post by peppy on Aug 11, 2021 16:27:15 GMT -5
Was anything mentioned about the new partnership with NRx? yes, first slide, working on several formulations including Zyesami. |
|
|
|
Post by cretin11 on Aug 11, 2021 16:29:37 GMT -5
Good to see that Afrezza is still the leadoff and primary focus of the presentation.
|
|
